BioWorld - Thursday, December 12, 2019

U.S.
%{topic} RSS Feed RSS

Novel technologies may drive tighter controls for ethylene oxide sterilization

December 9, 2019
By Mark McCarty
No Comments
The U.S. Environmental Protection Agency (EPA) has posted an advanced notice of proposed rulemaking for control of ethylene oxide emissions (EtO), which would update a 2006 final rule that declared no additional controls for EtO were necessary. However, the agency’s latest proposed rule makes note of several technological advances that allow for greater control of EtO, a fact that could drive a greater regulatory requirement for containment and destruction of EtO emissions at medical device sterilization plants.
Read More
Edwards-SAPIEN3-12-6.png

Edwards rolls out 2020 guidance with TAVR optimism, slow pace on mitral and tricuspid

December 6, 2019
By Stacy Lawrence
No Comments
Edwards Lifesciences Corp. added more than $20 billion so far this year to its market cap to exceed a $50 billion valuation. Executives worked to convince Wall Street that 2020 and beyond are lining up to be additional banner years for the cardiovascular med-tech giant at the company’s annual investor meeting. While the newly introduced guidance for next year from Edwards was largely in line or a bit better than analysts had anticipated, its share price remained relatively flat on the event.
Read More

U.S. health spending rises to $3.6T in 2018, but falls as share of GDP

December 6, 2019
By Mark McCarty
No Comments
Policymakers are often as sensitive to overall health care spending as they are to increases in Medicare spending, and the latest report on both brought some good news and some bad news. The good news is that overall health care spending was essentially flat as a share of gross domestic product (GDP) in 2018, but the bad news is that Medicare spending jumped 6.4%, thus renewing the troublesome historical trend of outpacing typical GDP growth.
Read More

FDA issues CRL for Enzyvant's congenital athymia therapy

December 5, 2019
By Michael Fitzhugh
No Comments
An FDA review of Enzyvant Inc.'s RVT-802, a tissue-based therapy for children born without a thymus, has drawn a complete response letter (CRL) from the agency over concerns about chemistry, manufacturing and controls, scuttling hopes it would become the first FDA-designated regenerative medicine advanced therapy (RMAT) to win approval from the agency.
Read More

DHIT, Tanjo team up to improve health via HUG in North Carolina

December 5, 2019
By Annette Boyle
No Comments
The Chapel Hill, N.C.-based non-profit Digital Health Institute for Transformation (DHIT) and Tanjo Inc., a machine learning company headquartered in Carrboro, N.C., will launch their Community Health Utility Grid (HUG) Initiative in North Carolina in early 2020. The collaboration aims to improve healthcare outcomes for underserved populations in the state by collecting, analyzing, and sharing individual, household and community level health data.
Read More
patent-law.png

Solicitor General fails to respond to petition for cert in Athena v. Mayo

December 4, 2019
By Mark McCarty
No Comments
The patent lawsuit of Athena v. Mayo revisits previous case law where patent subject matter eligibility is concerned, and numerous parties have weighed in urging the Supreme Court to hear the case. However, the U.S. Solicitor General has not responded with its own friend-of-the-court brief, an omission that would seem to take some of the pressure off the Supreme Court to hear the case.
Read More

Popular Stories

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe